Revvity has launched its EONIS Q system, a CE-IVD marked platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeﬁciency (SCID) in newborns.
For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time. However, to date, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests.
The EONIS Q system simpliﬁes and streamlines molecular testing for SMA and SCID with an innovative workﬂow, inclusive of the EONIS Q96 instrument, the EONIS SCID-SMA kit and dedicated EONIS EASI software.
“Helping children get a healthier start to life is at the heart of our work and making molecular testing for inherited conditions like SMA and SCID more accessible can help further that aim,” said Petra Furu, general manager of reproductive health at Revvity. “Without compromising quality, speed or test result accuracy, the EONIS Q system is designed to break down some of the common barriers that prevent newborn screening labs from adopting these tests.”
Turnaround time for the EONIS Q workﬂow from sample-in to result is approximately three hours, and compared to conventional wet qPCR solutions, the system exceeds industry standards in software capability. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time. Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware, further optimizing resource and cost efficiencies for labs looking to adopt the system.
The compact size and smaller physical footprint of the EONIS Q workﬂow is ideal for all lab sizes, while offering additional beneﬁts for low- and medium-throughput labs, including those without a PCR clean room.
The European Alliance for Newborn Screening in Spinal Muscular Atrophy, an advocacy group established by SMA Europe, mandates that by 2025, all newborns in Europe should be screened for SMA. The CE-IVD declaration of the EONIS Q system and other solutions like it advance progress toward achieving this goal.
For more information, visit: https://rh.perkinelmer.com/newborn-products/
Digital issue: Please click here for more information